The Economics of Hypercholesterolemia and Lipid-Lowering Therapy: A Brief Historical Tour

Value in Health

Volumn 1, Issue 3, 1998, Pages 159-165

  Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0013589288     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.1998.130159.x     Document Type: Conference Paper

References (19)

1. Berwick DM, Cretin S, Keeler H. Cholesterol, children, and heart disease: an analysis of alternatives. Pediatrics 1981;68(5):721-30.
2. Kannel W, Wolf P, Garrison R. The Framingham Study, Section 35: Survival Following Initial Cardiovascular Events. Bethesda, MD : National Heart, Lung and Blood Institute, 1988.
3. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
4. Oster G, Epstein AM. Primary prevention and coronary heart disease: the economic benefits of lowering serum cholesterol. Am J Public Health 1986; 76(6):647-56.
5. Garber AM, Weinstein MC, Torrance GW, Kamelt MS. Theoretical foundations of cost-effectiveness analysis. In: Gold MR, Siegel JF, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996:chap 2.
6. Russell LB. Is Prevention Better than Cure? Washington, DC: Brookings Institution, 1986.
7. Himmelstein DU, Wohlhandler S. Free care, cholestyramine and health policy. New Engl J Med 1984;311(23):1511-4.
8. Weinstein MC, Stason WB. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu Rev Public Health 1985;6:41-63.
9. Oster G, Epstein AM. Cost-effectiveness of antihyperlipidemic therapy in the prevention of coronary heart disease. The case of cholestyramine. JAMA 1987;258(17):2381-7.
10. Taylor WC, Pass TM, Shepard DS, et al. Cholesterol reduction and life expectancy: a model incorporating multiple risk factors. Ann Int Med 1987; 106(4):605-14.
11. Martens LL, Ruttens FF, Erkelens DW, et al. Cost-effectiveness of cholesterol-lowering therapy in the Netherlands. Simvastatin vs cholestyramine. Am J Med 1989;87(4A):54S-58S.
12. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991;265(9): 1145-51.
13. Weinstein MC, Coxson PG, Williams LW, et al. Forecasting coronary heart disease incidence, mortality and cost: the Coronary Heart Disease Policy Model. Am J Public Health 1987;77(11):1417-26.
14. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9.
15. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West Scotland Coronary Prevention Study Group. K Engl J Med 1995; 333:1301-7.
16. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
17. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996;93(10):1796-802.
18. Oster G, Borok GM, Menzin J, et al. Cholesterol Reduction Intervention Study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice. Arch Int Med 1996;156:731-9.
19. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 1967;20(8):637-48.